Skip to main content

Table 1 Characteristics of individuals included into the study

From: A targeted analysis reveals relevant shifts in the methylation and transcription of genes responsible for bile acid homeostasis and drug metabolism in non-alcoholic fatty liver disease

 

Discovery Group (n = 74)

Validation Cohorta (n = 54)

Expression correlation (EC) cohort

Expr. Analysis Cohort (n = 50)

Parameter

Control

SS

NASH

Control

SS & NASH

Control

SS

NASH

n

45

14

15

0

54

30

13

7

Men:Women (n (%))

8 (17.8):37 (82.2)

4 (28.6):10 (71.4)

4 (26.7):11 (73.3)

N/A

16 (29.6):38 (70.4)

15 (50.0):15 (50.0)

9 (69.2):4 (30.8)

7 (100.0):0 (0.0)

Age (years, Mean (SD))

49.2 (14.0)

46.5 (13.9)

45.1 (8.8)

N/A

51.2 (10.0)

62.1 (16.2)

41.3 (5.9)

53.9 (9.5)

Body mass index (BMI, Mean (SD))

33.9 (10.6)

48.5 (7.0)

48.5 (12.4)

N/A

35.9 (8.8)

26.6 (6.4)

53.9 (9.5)

52.5 (11.2)

Diabetes mellitus Type 2

36 no;4 nk;5 yes

9 no; 2 nk; 3 yes

10 no; 3 nk; 2 yes

N/A

36 no; 18 yes

Diabetic state nk

Fibrosis stage (n (%))b

        

 Insignificant

N/A

N/A

N/A

N/A

0 (0.0)

3 (10.0)

10 (76.9)

4 (57.1)

 Mild

N/A

N/A

N/A

N/A

32 (59.3)

0 (0.0)

3 (23.1)

2 (28.6)

 Advanced

N/A

N/A

N/A

N/A

22 (40.7)

0 (0.0)

0 (0.0)

1 (14.3)

Steatosis Gradec

        

  < 5 %

N/A

N/A

N/A

N/A

4 (7.4)

23 (76.6)

0 (0.0)

0 (0.0)

 5–33 %

N/A

N/A

N/A

N/A

23 (42.6)

7 (23.3)

2 (15.4)

0 (0.0)

 34–66 %

N/A

N/A

N/A

N/A

16 (29.6)

0 (0.0)

5 (38.5)

1 (14.3)

  > 66 %

N/A

N/A

N/A

N/A

11 (20.4)

0 (0.0)

5 (38.5)

5 (71.4)

 missing

      

1

1

  1. n absolute number, SD standard deviation, N/A not applicable, nk not known
  2. aAn exact subdivision NAFLD into SS or NASH was not provided in ArrayExpress
  3. bSeverity of fibrosis, evaluated as 0, 0.5, 1, 2 or N/A in the EC cohort, was matched to the fibrosis stage in the validation cohort (insignificant (non-fibrotic samples were not available in this cohort), mild, advanced) as following: ‘Mild’ (1), ‘Advanced’ (2), and ‘Insignificant’ (0 or 0.5)
  4. cThe strength of steatosis, defined as 0, 1, 2, 3 or N/A in the EC cohort was matched to the degree of steatosis in the validation cohort as following: ' < 5 %', 1 = '5–33 %', 2 = '34–66 %' and 3 = ' > 66 %'
Back to article page

BMC Genomics

ISSN: 1471-2164

Contact us